Clinical trial
MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients…
NCT00103857 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00103857 |
|---|---|
| Title | MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036) |
| Official title | A Multicenter, Randomized, Double-Blind Factorial Study of the Co-Administration of MK0431 and Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily), Comparator: MK0431 100 mg q.d. (q.d. = once daily), Comparator: Placebo (Phase A)/Metformin (Phase B), Comparator: Metformin 500 mg b.i.d., Comparator: Open-Label MK0431/Metformin 50/1000 mg b.i.d., Comparator: Metformin 1000 mg b.i.d. |
| Enrollment | 1,208 |
| Start date | Mar 17, 2005 |
| Primary completion | Jul 25, 2006 |
| Completion | Feb 21, 2008 |
| First posted | Feb 16, 2005 |
| Last update posted | May 5, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: